A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT07321678
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Ascletis Pharma (China) Co., Limited
- Registry
-
NCT07321678
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT07321678. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-22 (actual); primary completion 2026-08-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- ASC30 tablets
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
Record details
- Record id
cardio:ct-nct07321678- Content hash
42a1ac6f22b9f8399d943277ce27c7ad612697154ca5412fd53c08b3f0b86aee